Table 1.
BCLC-0 | BCLC-A | BCLC-B | BCLC-C | BCLC-D | |
(ablation, LR or LT) | (ablation, LR or LT) | (TACE) | (SOR) | (ST) | |
HKLC-I (ablation, LR or LT) | √ | √ | |||
HKLC-IIA (ablation, LR or LT) | √ | √ | |||
HKLC-IIB (LR) | √ | √ | |||
HKLC-IIIA (TACE) | √ | ||||
HKLC-IIIB (TACE) | √ | ||||
HKLC-IVA (SOR) | √ | ||||
HKLC-IVB (SOR or ST) | √ | ||||
HKLC-VA (LT) | |||||
HKLC-VB (ST) | √ |
The tick in the table means that there was agreement in the treatment of HCC proposed by the HKLC system and BCLC classification. BCLC: Barcelona clinic liver cancer; HCC: Hepatocellular carcinoma; HKLC: Hong Kong liver cancer; LR: Liver resection; LT: Liver transplantation; ST: Symptomatic treatment; SOR: Sorafenib; TACE: Transarterial chemoembolization.